B cell targeted therapies in autoimmune disease.
B cell targeted therapies in autoimmune disease.
Curr Opin Immunol. 2019 Nov 13;61:92-99
Authors: Barnas JL, Looney RJ, Anolik JH
Abstract
PURPOSE OF REVIEW: FDA-approved B cell-targeted therapy has expanded to a multitude of autoimmune diseases ranging from organ specific diseases, like pemphigus and multiple sclerosis, to systemic diseases such as ANCA-associated vasculitis, rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). In this review, we discuss the variability in response to B cell-targeted therapies with a focus on the diversity of human B cells and plasma cells, and will discuss several of the promising new B cell-targeted therapies.
RECENT FINDING: The pathogenic roles for B cells include autoantibody-dependent and autoantibody-independent functions whose importance may vary across diseases or even in subsets of patients with the same disease. Recent data have further demonstrated the diversity of human B cell subsets that contribute to disease as well as novel pathways of B cell activation in autoimmune disease. The importance of eliminating autoreactive B cells and plasma cells will be discussed, as well as new approaches to do so.
SUMMARY: The past several years has witnessed significant advances in our knowledge of human B cell subsets and function. This has created a nuanced picture of the diverse ways B cells contribute to autoimmunity and an ever-expanding armamentarium of B cell-targ...
Source: Current Opinion in Immunology - Category: Allergy & Immunology Authors: Barnas JL, Looney RJ, Anolik JH Tags: Curr Opin Immunol Source Type: research
More News: Allergy & Immunology | Arthritis | Autoimmune Disease | Lupus | Multiple Sclerosis | Pemphigus | Rheumatoid Arthritis | Rheumatology | Vasculitis